The invention refers to tablet form with controlled release of Varenicline, which is used in the pharmacy and medicine and especially to reduce the nicotine addiction, to support the suspension and limit the use of tobacco products. The tablet can be with one-layer or two-layer core which is formed from the active substance Varenicline free base and the excipients mannitol, cellulose powder, magnesium stearate and hydroxypropyl methylcellulose with molecular weight from 100 000 to 200 000. The advantage of the tablet form with controlled release, according to the invention, is its good stability, uniformity of content and good bioavailability, with low amplitude of Cmax and Cmjn and possibility to overcome the side effects from the rapid release of Varenicline as nausea and headache.